Genomics England is working with the NHS to deliver and improve genomic testing to help clinicians to diagnose, treat and prevent illnesses including cancer and rare disease. They provide health data and technology needed to enable and support the development of medicines and medical discoveries to improve healthcare for patients and their families.
National Institute for Health Research
The National Institute for Health Research is a key partner in the delivery of the UK Rare Diseases Framework, published in January 2021 which sets out a national vision on how the UK will improve the lives of those living with rare diseases.
Whole genome sequencing (WGS) in the NHS Genomics Medicine Service (GMS) will involve a ‘Patient Choice’ consent model, which covers both the clinical implications of a test as well as an offer to participate in the National Genomic Research Library (NGRL), within the clinical pathway. The NGRL is a national initiative with support from NHSE/I, Genomics England, and the Department of Health and Social Care (DHSC).
Genomics England is a company wholly owned by the DHSC, set up initially to deliver the 100,000 Genomes Project. NB: The NGRL is not part of the National Institute for Health Research Clinical Research Network Portfolio of studies.
National Genomic Research Library: information for clinicians - Genomics Education Programme